A Real-World Observational Study of Second-Line Anti-TNFα Treatment in Patients with Ulcerative Colitis who Received Vedolizumab as a First-Line Biologic
- DOI
- 10.1093/crocol/otag042
- Published
- 2026-05-15
- Container
- Crohn's & Colitis 360
- Publisher
- Oxford University Press (OUP)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1093/crocol/otag042,
title = {A Real-World Observational Study of Second-Line Anti-TNFα Treatment in Patients with Ulcerative Colitis who Received Vedolizumab as a First-Line Biologic},
author = {Chiahung Chou and Marie Sanchirico and Precious A Anyanwu and Lucinda J Van Anglen and Timothy E Ritter},
year = {2026},
journal = {Crohn's \& Colitis 360},
doi = {10.1093/crocol/otag042},
url = {https://doi.org/10.1093/crocol/otag042}
}RIS
TY - JOUR TI - A Real-World Observational Study of Second-Line Anti-TNFα Treatment in Patients with Ulcerative Colitis who Received Vedolizumab as a First-Line Biologic AU - Chiahung Chou AU - Marie Sanchirico AU - Precious A Anyanwu AU - Lucinda J Van Anglen AU - Timothy E Ritter PY - 2026 JO - Crohn's & Colitis 360 DO - 10.1093/crocol/otag042 UR - https://doi.org/10.1093/crocol/otag042 ER -
APA
Chou, C., Sanchirico, M., Anyanwu, P. A., Anglen, L. J. V., & Ritter, T. E. (2026). A Real-World Observational Study of Second-Line Anti-TNFα Treatment in Patients with Ulcerative Colitis who Received Vedolizumab as a First-Line Biologic. Crohn's & Colitis 360. https://doi.org/10.1093/crocol/otag042
Source records
- crossref · retrieved 2026-09-27T15:49:44.660Z